WILEX subsidiary Heidelberg Pharma to present at two upcoming scientific conferences

PDF Download

Munich, Germany, 09 April 2015 – WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) today announced that its subsidiary Heidelberg Pharma GmbH will present at two upcoming scientific conferences.

Antibody/Targeted Drug Conjugates (ATDC 2015)
Professor Andreas Pahl, CSO of Heidelberg Pharma, will give a talk on “Improvement of the therapeutic index of amanitin-based ADCs” at the ATDC to be held in Porto, Portugal, on 13-15 April 2015. The talk is scheduled to take place on Tuesday, 14 April 2015 at 4:15 PM GMT in Session 7: ADC Development.

Annual Meeting of the American Association for Cancer Research (AACR 2015)
At the AACR in Philadelphia, Pennsylvania, taking place from 18 to 22 April 2015, a poster presentation regarding amanitin-based ADCs will be given by Dr Jan Anderl, Director Biochemistry and Cell Biology of Heidelberg Pharma, on Sunday, 19 April 2015, 1:00 PM – 5:00 PM EDT in Section 27. The abstract is available online on the AACR website: http://www.aacr.org.

About WILEX and Heidelberg Pharma
WILEX AG is a biopharmaceutical company which has a ready for partnering portfolio of antibody-based diagnostic and therapeutic Phase III product candidates for the detection and targeted treatment of clear cell renal cell carcinoma. Research and development focus on the operations of its subsidiary Heidelberg Pharma GmbH in Ladenburg, which primarily advances the development of the innovative platform technology for antibody drug conjugates (ADC technology) and provides pre-clinical drug discovery and development services. WILEX is listed at the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at http://www.wilex.com/.


Sylvia Wimmer
Corporate Communications
Tel.: +49 (0)89-41 31 38-29
Email: investors[at]wilex.com
Grillparzerstr. 10, 81675 Munich, Germany
IR/PR support
MC Services AG

Katja Arnold (CIRO)
Executive Director
Tel.: +49-89-210 228-40
Mobil: +49 160 9360 3022
Email: katja.arnold[at]mc-services.eu
Business Development
Heidelberg Pharma GmbH

Dr Marcel Linssen
CBO, Executive Vice President
Tel.: +49-(0) 6203 1009-40
Email: m.linssen[at]hdpharma.com 

This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward- looking statements to reflect future events or developments.

Seite gelesen: 523 | Heute: 2